FY2024 · ended Dec 31, 2024 · Revenue $601,000, +5.4% YoY · Filed Apr 15, 2025
Vaccinex, Inc. (VCNX) files with the SEC under industry code 2834, Pharmaceutical Preparations. In fiscal 2024, which ended Dec 31, 2024, it reported revenue of $601,000 and a net loss of $18.6 million. Free cash flow was -$16.2 million. As of Dec 31, 2024 it held $1.1 million in cash and investments and $25,000 in total debt.
Revenue
$601,000
+5.4% vs prior year
Net income
$-18.63M
+8.0% vs prior year
Operating cash flow
$-16.19M
+24.3% vs prior year
Free cash flow
$-16.21M
+24.4% vs prior year
EPS
$-8.88
+79.7% vs prior year
Dividend per share
None
Shares outstanding
2.68M
+117.3% vs prior year
Net cash
$1.08M
FY 2024
Operating margin
-3117.3%
FY 2024
Company profile
- Industry
- Pharmaceutical Preparations (SIC 2834)
- Listed as
- VCNX (OTC)
- Fiscal year ends
- December 31
- Incorporated in
- DE
- Headquarters
- Rochester, NY
- SEC filer status
- Non-accelerated filer, Smaller reporting company
- SEC CIK
- 1205922
- Former names
- VACCINEX INC (until May 9, 2005)
Other Pharmaceutical Preparations companies
- ELI LILLY & Co LLY
- Johnson & Johnson JNJ
- AbbVie Inc. ABBV
- Merck & Co., Inc. MRK
- Novartis AG NVS
- Astrazeneca PLC AZN
- Abbott Laboratories ABT
- Novo Nordisk A S NVO
Key figures
Fiscal-year totals from the annual reports. Balance sheet lines are as of each year end.
| Line | FY 2024 Dec 31, 2024 |
FY 2023 Dec 31, 2023 |
FY 2022 Dec 31, 2022 |
FY 2021 Dec 31, 2021 |
FY 2020 Dec 31, 2020 |
|---|---|---|---|---|---|
| Revenue | $601,000 | $570,000 | $275,000 | $900,000 | $625,000 |
| Operating income | -$18.7M | -$22.9M | -$19.9M | -$22.5M | -$28.3M |
| Net income | -$18.6M | -$20.3M | — | -$22.4M | -$28.9M |
| Diluted EPS | -$8.88 | -$43.68 | -$98.05 | — | — |
| Operating cash flow | -$16.2M | -$21.4M | -$19.1M | -$25.3M | -$28.6M |
| Free cash flow | -$16.2M | -$21.4M | -$19.2M | -$25.3M | -$28.9M |
| Total assets | $2.6M | $3.6M | $8.0M | $9.8M | $11.7M |
| Total liabilities | $5.1M | $5.9M | $2.8M | $2.4M | $14.3M |
| Stockholders' equity | -$2.5M | -$2.3M | $5.2M | $7.4M | -$2.6M |
| Cash and investments | $1.1M | $1.5M | $6.4M | $8.6M | $10.6M |
| Total debt | $25,000 | $246,764 | $484,850 | $389,561 | $1.1M |
Recent SEC filings
| Form | Description | Filed | Period |
|---|---|---|---|
| 10-K | Annual report | Apr 15, 2025 | Dec 31, 2024 |
| 8-K |
Current report
Officer or director change
|
Mar 19, 2025 | Mar 18, 2025 |
| 8-K |
Current report
Listing notice, Regulation FD disclosure
|
Mar 7, 2025 | Mar 7, 2025 |
| 8-K |
Current report
Listing notice, Other events
|
Dec 17, 2024 | Dec 16, 2024 |
| 8-K |
Current report
Material agreement, Unregistered share sale
|
Nov 14, 2024 | Nov 13, 2024 |
| 10-Q | Quarterly report | Nov 14, 2024 | Sep 30, 2024 |
All 475 Vaccinex, Inc. SEC filings
Source: SEC EDGAR filings. This is company-reported data, not investment advice.